Zusammenfassung
Die antiretrovirale Kombinationstherapie ist Scit 1996 „Gold-Standard” in der Behandlung der HIV-Infektion. Die Hemmung der Virusreplikation durch eine antiretrovirale Therapie (ART) verhindert die Krankheits-Progression, führt zur Rückbildung HIV-bedingter Symptome bzw. Erkrankungen und führt zu einer klinisch relevanten Immunrekonstitution. Der Rückgang der Morbidität, Mortalität und Hospitalisierungstage wurde beobachtet (1,2).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Egger M et al (1997) Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multi-center study. Swiss HIV Cohort Study. British Medical Journal 315: 1194–1199
Palella FJ Jr et al (1998) Declining morbidity and mortality among patients with advanced immunodeficiency virus infection. HIV Outpatient Study Investigators. New England J Medicine 338: 853–860
Tavel JA, Miller KD, Masur H (1999) Guide to major clinical trials of anti-retroviral therapy in human immune deficiency virus infected patients: protease inhibitors, non-nucleoside reverse transcriptase inhibitors, and nucleoside reverse transcriptase inhibitors. Clinical Infectious Disease Journal 28: 643–76
Staszewski S et al (1999) The Study 006 Team. Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir and Indinavir plus Zidovudine and Lamivudine in the treatment of HIV infection in adults. New England Journal of Medicine 341 (25): 1865–1873
Staszewski S et al (2001) And the CNAAB3005 International Study Team. Abacavir-lamivudine-zidovudine vs indina-vir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial. JAMA 285: 1155–1163
Baxter JD, Mayers DL, Ventworth DN, CT-CRA046 Study Team (1999) Pilotstudy of the short term effects of antiretroviral management based on plasma genotype antiretroviral resistant testing (GART) in patients failing antiretroviral therapy. In: Proceedings of 6th Conference on Retroviral and Opportunistic Infection, Chicago, Abstract LD820
Durant J et al (1999) Drug resistance geno-typing in HIV 1 therapy: a VIRADAPT randomised controlled trial. Lancet 353: 2195–2199
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer-Verlag Wien
About this chapter
Cite this chapter
Gartner, M. (2003). Antiretrovirale HIV-Therapie. In: Beubler, E., Haltmayer, H., Springer, A. (eds) Opiatabhängigkeit. Springer, Vienna. https://doi.org/10.1007/978-3-7091-3796-3_10
Download citation
DOI: https://doi.org/10.1007/978-3-7091-3796-3_10
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-83793-1
Online ISBN: 978-3-7091-3796-3
eBook Packages: Springer Book Archive